Hypothalamic–pituitary–somatotropic axis Hypothalamic–pituitary–somatotropic axis The hypothalamic–pituitary–somatotropic axis (HPS axis), or hypothalamic–pituitary–somatic axis, also known as the hypothalamic–pituitary–growth axis, is a hypothalamic–pituitary axis which includes the secretion of growth hormone (GH; somatotropin) from the somatotropes of the pituitary gland into the circulation and the subsequent stimulation of insulin-like growth factor 1 (IGF-1; somatomedin-1) production by GH in tissues such as, namely, the liver. Other hypothalamic–pituitary hormones such as growth hormone-releasing hormone (GHRH; somatocrinin), growth hormone-inhibiting hormone (GHIH; somatostatin), and ghrelin () are involved in the control of GH secretion from the pituitary gland. The HPS axis is involved in postnatal human growth. Individuals
Pituitary pars intermedia dysfunction increased predisposition to infection usually take between 30 days and 1 year to improve. Cyproheptadine may be added to the treatment regime in horses that are inadequately responding to pergolide, but is usually only used in horses with advanced PPID on high doses of pergolide. Pituitary pars intermedia dysfunction Pituitary pars intermedia dysfunction (PPID), or equine Cushing's disease, is an endocrine disease affecting the pituitary gland of horses. It is most commonly seen in older animals, and is classically associated with the formation of a long, wavy coat (hirsutism) and chronic laminitis. Unlike the human and canine forms of Cushing's